Level Zero Health is a London‑based biotech startup building minimally invasive, DNA‑based wearable sensors for continuous hormone monitoring, starting with reproductive and testosterone-related applications and targeting clinicians, fertility clinics and eventually consumers and pharma partners.[6][5]
High‑Level Overview
- Mission: Develop continuous, clinically accurate hormone monitoring to empower patients and clinicians with real‑time hormonal data and to build the world’s largest hormone‑health dataset for research and personalized care.[6][5]
- Investment philosophy / Key sectors / Impact on startup ecosystem (if treated as an investment firm): Not applicable — Level Zero Health is a portfolio company/startup rather than an investor; it has been backed by investors including Redalpine and HAX and raised a £5.5M pre‑seed round led by Redalpine, which positions it as one of the largest female‑founder pre‑seed raises in Europe.[1][5]
- What product it builds: A minimally invasive wearable patch that uses DNA/aptamer‑based biosensors and microneedle/microfluidic chemistry to continuously measure hormones from interstitial fluid (and in prototype form via colourimetric patch read by camera), providing real‑time hormone readings and longitudinal hormone trends.[6][1][5]
- Who it serves: Initial customers are clinical B2B users — IVF clinics and clinicians treating testosterone deficiency and reproductive endocrinology — with a roadmap toward B2C and pharma research partnerships.[5][1][2]
- What problem it solves: Current hormone testing is intermittent (single blood draws) and poorly captures dynamic hormone physiology; Level Zero Health aims to provide continuous, actionable biochemical data to improve fertility care, dosing decisions and personalized hormone management.[5][1]
- Growth momentum: Founded in late 2023 and rapidly advanced R&D through 2024–2025, Level Zero Health validated DNA‑based sensors across ~98% of the human clinical hormone range in simulated/clinical work, compiled LOIs from IVF clinics, filed broad patents, built prototypes, and closed a £5.5M pre‑seed round led by Redalpine in early 2025.[3][1][5]
Origin Story
- Founders & backgrounds: Co‑founded by CEO Ula Rustamova (ex‑Palantir enterprise tech lead and prior wearable founder) and CTO Irene Jia (medical device R&D at Philips), supported by founding research staff with academic backgrounds in bioengineering, MEMS, biosensors and microfluidics.[1][6]
- How the idea emerged: The team identified a gap analogous to continuous glucose monitoring — hormones are central to health but only intermittently measured — and pursued DNA/aptamer biosensors plus microneedle/patch form factors to enable continuous monitoring from interstitial fluid.[5][1]
- Early traction / pivotal moments: In under a year the company validated sensor performance across the human clinical range (reported ~98% accuracy in simulated tests), filed broad patents in 2024, developed working prototypes including a colourimetric snapshot patch, secured LOIs from major IVF clinics and closed a £5.5M pre‑seed raise led by Redalpine in 2025.[1][5][6]
Core Differentiators
- Novel sensing chemistry: Uses DNA/aptamer‑based biosensors (reported as aptamer/DNA sensors) capable of extended hormone detection with claimed clinical‑range accuracy, differentiating from antibody or enzyme chemistries common in POC tests.[1][5]
- Continuous monitoring focus: Targets continuous, longitudinal hormone measurement (analogous to CGM in diabetes) rather than episodic blood tests, unlocking temporal patterns clinicians currently miss.[5][1]
- Minimally invasive wearable form factor: Microneedle/microfluidic patch concept and colourimetric snapshot prototypes aim to combine clinical accuracy with wearable convenience and potential for camera/readout interoperability.[5][6]
- Early clinical and commercial engagement: Reported LOIs from IVF clinics and a go‑to‑market plan prioritizing clinical B2B while preserving B2C and pharma expansion options.[5][1]
- Team and IP: Founders with deep device and software backgrounds, rapid patenting and academic R&D hires provide technical moat and translational capability.[6][1]
Role in the Broader Tech Landscape
- Trend they’re riding: The move from episodic lab diagnostics to continuous biosensing and personalized longitudinal health data (following CGM’s model) alongside advances in aptamer therapeutics/sensors and wearable medtech.[5][1]
- Why timing matters: Regulatory progress on nucleic‑acid/aptamer tools, increasing demand in reproductive health and fertility care, and growing clinical appetite for real‑time biomarkers create a market window for hormone CGM‑style products.[5][1]
- Market forces in their favor: Large addressable markets (fertility, endocrine care, men’s health, pharma trials), momentum in wearable monitoring adoption, and the value of high‑resolution hormone datasets for personalized medicine and drug development.[5][6]
- Influence on ecosystem: If successful, Level Zero Health could catalyze new standards for hormone monitoring, enable data‑driven reproductive care, accelerate pharma development that depends on hormone dynamics, and stimulate startups building analytics and digital therapeutics on top of continuous hormone streams.[5][1]
Quick Take & Future Outlook
- What’s next: Near term — completing clinical R&D milestones, regulatory pathway definition, pilot deployments with IVF clinics and refinement of wearable prototypes; medium term — regulatory clearance, scaling manufacturing, expanding analyte panel and pursuing B2C offerings or pharma partnerships for trials.[1][5][6]
- Trends that will shape them: Regulatory acceptance of aptamer/oligonucleotide biosensors, cost and reliability of microneedle wearables, clinician adoption of continuous biochemical data, and the emergence of AI/analytics for longitudinal hormonal signals.[5][1]
- How their influence might evolve: Success would position Level Zero Health as a foundational data layer in hormone health, enabling new clinical workflows, personalized dosing, and research insights; failure risks include technical translation hurdles, regulatory delays, or slower-than‑expected clinical adoption.[1][5]
Quick take: Level Zero Health is an early‑stage, technically ambitious medtech startup that has moved rapidly from concept to pre‑seed funding, prototypes and clinic interest by combining DNA/aptamer biosensing with wearable microneedle form factors; its ability to navigate clinical validation and regulatory pathways will determine whether it becomes the hormone‑monitoring analogue to CGM or remains an intriguing R&D story.[5][1][6]
